The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 | Zendy

Ofri Mosenzon | Zendy; Stephen D. Wiviott | Zendy; Hiddo J.L. Heerspink | Zendy; Jamie P. Dwyer | Zendy; Avivit Cahn | Zendy; Erica L. Goodrich | Zendy; Aliza Rozenberg | Zendy; Meir Schechter | Zendy; Ilan Yanuv | Zendy; Sabina A. Murphy | Zendy; Thomas A. Zelniker | Zendy; Ingrid GauseNilsson | Zendy; Anna Maria Langkilde | Zendy; Martin Fredriksson | Zendy; Peter A. Johansson | Zendy; Deepak L. Bhatt | Zendy; Lawrence A. Leiter | Zendy; Darren K. McGuire | Zendy; John Wilding | Zendy; Marc S. Sabatine | Zendy; Itamar Raz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Author(s) -

Ofri Mosenzon,

Stephen D. Wiviott,

Hiddo J.L. Heerspink,

Jamie P. Dwyer,

Avivit Cahn,

Erica L. Goodrich,

Aliza Rozenberg,

Meir Schechter,

Ilan Yanuv,

Sabina A. Murphy,

Thomas A. Zelniker,

Ingrid GauseNilsson,

Anna Maria Langkilde,

Martin Fredriksson,

Peter A. Johansson,

Deepak L. Bhatt,

Lawrence A. Leiter,

Darren K. McGuire,

John Wilding,

Marc S. Sabatine,

Itamar Raz

Publication year - 2021

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-0076

Subject(s) - albuminuria , dapagliflozin , medicine , renal function , creatinine , urology , kidney disease , diabetes mellitus , timi , type 2 diabetes , placebo , endocrinology , myocardial infarction , pathology , percutaneous coronary intervention , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research